Ang MK, Montoya JE, Tharavichitkul E, et al. - A phase 2 study was conducted to assess whether a combination of nimotuzumab (a humanized monoclonal antibody to the epidermal growth factor receptor) and chemoradiation is effective in treating patients suffering from locally advanced head and neck squamous cell carcinoma (HNSCC). Experts administered 3‐weekly cisplatin 100 mg/m ² for three cycles and weekly nimotuzumab 200 mg for 8 weeks concurrently with radiotherapy to patients having stage III/IV HNSCC. In this study with 37 patients, best overall response of complete and partial response was identified in 22/37 (59%) and 10/37 (27%) patients, respectively. A median progression‐free survival (PFS) of 17.5 months and 3‐year PFS of 40.4% was reported. Findings demonstrated safety of the combination of nimotuzumab with cisplatin and radiotherapy in treating HNSCC, and this combination conferred high response rates in these patients.